Jardiance EMA vs FDA Approach: How Empagliflozin Regulatory Paths Diverge

FDA Approval Timeline for Empagliflozin

The FDA approved empagliflozin on August 1, 2014 under NDA 204629, making it the fourth SGLT2 inhibitor available in the United States [2]. The initial indication was restricted to improving glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise. What followed was one of the most consequential label expansion trajectories in modern endocrinology.

Initial Type 2 Diabetes Indication

The original FDA review relied on phase III data showing empagliflozin 25 mg reduced HbA1c by approximately 0.7% versus placebo over 24 weeks [3]. The FDA required a cardiovascular outcomes trial (CVOT) as a post-marketing commitment, a standard condition for all new diabetes drugs since the 2008 FDA guidance on CV risk assessment. That requirement produced the trial that would reshape the SGLT2 class.

The Cardiovascular Death Breakthrough

EMPA-REG OUTCOME (N=7,020) enrolled patients with type 2 diabetes and established cardiovascular disease across 42 countries [1]. Published in September 2015, the trial showed empagliflozin reduced the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 14% (HR 0.86, 95% CI 0.74 to 0.99). The cardiovascular death result was striking: a 38% relative risk reduction (HR 0.62, 95% CI 0.49 to 0.77). Hospitalization for heart failure dropped 35%.

On December 2, 2016, the FDA granted empagliflozin a supplemental approval to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease [2]. This made Jardiance the first diabetes medication in the SGLT2 class to carry an explicit CV death reduction claim on its US label.

Heart Failure and CKD Expansions

The EMPEROR program generated two more milestones. EMPEROR-Reduced (N=3,730) showed empagliflozin cut the combined risk of cardiovascular death or hospitalization for heart failure by 25% in patients with heart failure and reduced ejection fraction (HR 0.75, 95% CI 0.65 to 0.86) [4]. EMPEROR-Preserved (N=5,988) demonstrated a 21% reduction in the same composite among patients with heart failure and preserved ejection fraction (HR 0.79, 95% CI 0.69 to 0.90) [5].

The FDA approved empagliflozin for heart failure in adults in February 2022, covering the full ejection fraction spectrum without restricting to a specific LVEF cutoff. A separate approval for chronic kidney disease followed, grounded in the EMPA-KIDNEY trial [6].

EMA Authorization Path for Empagliflozin

The European Medicines Agency granted marketing authorization for empagliflozin through the centralized procedure on May 22, 2014 [7]. The centralized procedure means a single application to the EMA results in authorization valid across all EU member states, eliminating the need for country-by-country review.

Centralized Procedure and the CHMP

The Committee for Medicinal Products for Human Use (CHMP) evaluated the initial application based on the same phase III dataset that the FDA reviewed. However, the EMA's European Public Assessment Report (EPAR) placed greater emphasis on the active-comparator data against glimepiride, reflecting the European regulatory preference for relative efficacy assessments over placebo-only data [7].

The initial authorized indication mirrored the FDA's: treatment of type 2 diabetes mellitus in adults to improve glycemic control. The EMA approved both the 10 mg and 25 mg doses, consistent with the FDA.

Type II Variations for New Indications

EMA label expansions proceed through "type II variations," a formal regulatory pathway for significant changes to the terms of marketing authorization. After EMPA-REG OUTCOME data became available, the CHMP recommended updating the Summary of Product Characteristics (SmPC) to include the cardiovascular outcome data in 2016 [7].

A key difference from the FDA approach: the EMA initially incorporated the CV data into the clinical trial results section of the SmPC rather than adding a distinct therapeutic indication for CV death reduction. The FDA, by contrast, added a separate, standalone indication line. This distinction matters for prescribers interpreting what the label technically authorizes versus what the data support.

For the heart failure indication, the EMA authorized empagliflozin for "symptomatic chronic heart failure" in adults, while the FDA approved it for "heart failure in adults." The EMA wording requires symptoms to be present. The FDA wording does not.

How EMPA-REG OUTCOME Shaped Both Labels

EMPA-REG OUTCOME was not designed as a superiority trial. Its primary objective was to demonstrate cardiovascular safety (non-inferiority against placebo for major adverse cardiovascular events). The superiority finding on cardiovascular death was a secondary endpoint result that both agencies chose to act on, each through their own regulatory logic [1].

Trial Design Specifics

The trial randomized 7,020 patients with type 2 diabetes, established cardiovascular disease, and an eGFR of at least 30 mL/min/1.73 m² to empagliflozin 10 mg, empagliflozin 25 mg, or placebo. Median follow-up was 3.1 years. The primary composite endpoint (three-point MACE) reached statistical significance, but the individual MACE components diverged: cardiovascular death dropped significantly, while nonfatal MI and nonfatal stroke did not reach significance individually [1].

Label Language Compared

The FDA labeled empagliflozin with a clear indication statement: "to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease" [2]. The agency treated the CV death finding as strong enough for an independent indication.

The EMA adopted a more conservative posture. The CHMP updated the SmPC to include the EMPA-REG OUTCOME results in section 5.1 (pharmacodynamic properties) and allowed mention in section 4.1 (therapeutic indications) with reference to the CV data [7]. The practical effect was similar (prescribers could cite the CV benefit), but the regulatory architecture differed. The EMA's approach reflected its tradition of embedding outcomes data within the broader SmPC framework rather than issuing discrete indication expansions for each finding.

Dr. Silvio Inzucchi, who served on the EMPA-REG OUTCOME steering committee, noted in a 2016 commentary: "The cardiovascular death reduction was unprecedented in magnitude for a glucose-lowering agent, and both regulators recognized it, albeit through different procedural channels" [8].

Heart Failure Indications: Regulatory Divergence in Practice

The heart failure approvals reveal the sharpest divergence between the two agencies. Both relied on the same EMPEROR trial program. Both reached favorable conclusions. The scope of what they authorized differed.

EMPEROR-Reduced and EMPEROR-Preserved

EMPEROR-Reduced enrolled patients with LVEF ≤40% and NYHA class II-IV symptoms [4]. The 25% risk reduction in the primary composite was driven primarily by reduced heart failure hospitalizations. Cardiovascular death alone did not reach significance in this trial (HR 0.92, 95% CI 0.75 to 1.12).

EMPEROR-Preserved enrolled patients with LVEF >40% [5]. The 21% risk reduction was again driven largely by hospitalization, not mortality. The EMA and FDA both evaluated pooled analyses of the two EMPEROR trials through the EMPEROR-Pooled program (N=9,718) [9].

How Each Agency Framed the Indication

The FDA approved empagliflozin for "heart failure in adults" without specifying ejection fraction or symptom requirements [2]. This broad language gave prescribers flexibility across the HF spectrum and allowed use in both HFrEF and HFpEF without label constraints.

The EMA authorized empagliflozin for "symptomatic chronic heart failure," requiring the presence of symptoms [7]. This wording aligns with how the EMPEROR trials enrolled patients (NYHA class II-IV), but it technically excludes asymptomatic patients or those in NYHA class I. The practical effect: a European prescriber treating an asymptomatic patient with HFpEF would be prescribing off-label, while an American prescriber in the same scenario would be within label.

The American College of Cardiology and American Heart Association's 2022 heart failure guidelines list empagliflozin as a Class I recommendation for HFrEF and a Class 2a recommendation for HFpEF, regardless of diabetes status [10].

Chronic Kidney Disease: The Third Indication Wave

EMPA-KIDNEY (N=6,609) randomized patients with CKD to empagliflozin 10 mg or placebo [6]. The trial was stopped early for efficacy after a median follow-up of 2.0 years. The primary composite of kidney disease progression or cardiovascular death fell 28% (HR 0.72, 95% CI 0.64 to 0.82, P<0.001).

Patient Population Differences

EMPA-KIDNEY enrolled a broader CKD population than EMPA-REG OUTCOME. Roughly 46% of patients did not have diabetes. EGFR ranged from 20 to 45 mL/min/1.73 m² (or 45 to 90 with a urine albumin-to-creatinine ratio of at least 200 mg/g). This allowed both regulators to extend the CKD indication beyond patients with type 2 diabetes [6].

Regulatory Alignment on CKD

On the CKD indication, the FDA and EMA reached more similar conclusions than they had for heart failure. Both authorized empagliflozin to reduce the risk of kidney disease progression in adults with chronic kidney disease at risk of progression. The FDA's CKD indication does not require concomitant diabetes. The EMA's position was comparable.

The KDIGO 2024 clinical practice guideline for CKD management recommends SGLT2 inhibitors, including empagliflozin, for patients with an eGFR ≥20 mL/min/1.73 m² and significant albuminuria, regardless of diabetes status [11].

Post-Market Safety Monitoring

Both agencies maintain active surveillance programs for empagliflozin, but the mechanisms differ substantially.

FDA Sentinel System and FAERS

The FDA monitors empagliflozin through its Sentinel System, a distributed data network that queries electronic health records and claims databases covering over 100 million patients [2]. The FDA Adverse Event Reporting System (FAERS) collects spontaneous reports from clinicians and patients. Key safety signals the FDA has tracked include diabetic ketoacidosis (DKA), Fournier's gangrene, and urinary tract infections.

In 2015, the FDA issued a Drug Safety Communication warning about DKA in patients using SGLT2 inhibitors, including empagliflozin [12]. The warning highlighted that DKA occurred at lower-than-expected blood glucose levels (euglycemic DKA), a presentation that could delay diagnosis. The FDA required label updates across the SGLT2 class.

EMA Periodic Safety Update Reports

The EMA requires marketing authorization holders to submit Periodic Safety Update Reports (PSURs) at defined intervals. The Pharmacovigilance Risk Assessment Committee (PRAC) evaluates these reports and can recommend label changes or risk minimization measures. The EMA issued similar warnings about DKA and genital infections, and the PRAC recommended SmPC updates for the SGLT2 class in 2016 [7].

A 2020 meta-analysis published in The Lancet Diabetes & Endocrinology (N=77,242 across four SGLT2 inhibitor CVOTs) found no increase in major adverse events with SGLT2 inhibitors, but confirmed elevated rates of genital mycotic infections (OR 3.56) and diabetic ketoacidosis (OR 2.46) [13].

Lower Limb Amputation: A Signal That Diverged by Drug

The FDA added a boxed warning about lower limb amputation risk to canagliflozin in 2017 but did not extend this warning to empagliflozin. EMPA-REG OUTCOME data showed no increased amputation risk with empagliflozin [1]. The EMA took a class-level approach initially but later aligned with a drug-specific assessment. This differential handling illustrates how each agency weighs class-effect assumptions against molecule-specific trial data.

What This Means for Prescribers

Clinicians prescribing empagliflozin in the US and Europe are working with the same drug and the same trial evidence. The regulatory framing creates practical differences.

A US prescriber can initiate empagliflozin for heart failure regardless of symptom status. A European prescriber needs documented symptoms to prescribe within label. Both can use it for CKD without a diabetes diagnosis.

The ADA's 2024 Standards of Care recommend SGLT2 inhibitors with proven cardiovascular benefit, including empagliflozin, for patients with type 2 diabetes and established atherosclerotic cardiovascular disease, heart failure, or CKD [14]. The European Society of Cardiology's 2023 guidelines provide parallel recommendations but reference the EMA-approved indications [15].

For patients traveling between jurisdictions or transferring care internationally, the label differences rarely change clinical management. The evidence base is identical. The regulatory packaging around that evidence is not.

Empagliflozin 10 mg once daily is the standard dose for heart failure and CKD indications in both jurisdictions. For glycemic control, the dose may be increased to 25 mg daily if tolerated [2].